A Washington University in St. Louis (U.S.) international tax law expert says this deal is the biggest merger involving tax inversion, i.e., relocation of a corporation's legal domicile to a lower-tax nation, usually while retaining operations in its higher-tax country. "None of the special anti-inversion laws and regulations issued by the federal government will apply to Pfizer post-merger," Professor Adam Rosenzweig, JD, said. Rosenzweig believes this deal will encourage more U.S. companies to follow Pfizer's approach in future mergers. (Washington University)U.S. job growth for October 2015 saw the biggest gains since December 2014, fueling hopes that the Federal Reserve Board will increase near-zero interest rates at its December meeting. (Reuters)